

Efficient synthesis of mono- and disubstituted 2,3-dihydroquinazolin-4(1*H*)-ones using $\text{KAl}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$ as a reusable catalyst in water and ethanol

Minoo Dabiri,^{a,*} Peyman Salehi,^b Somayeh Otokesh,^a Mostafa Baghbanzadeh,^a Gholamreza Kozehgari^a and Ali A. Mohammadi^a

^aDepartment of Chemistry, Faculty of Sciences, Shahid Beheshti University, Tehran 1983963113, Iran

^bDepartment of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Tehran 19835-389, Iran

Received 12 April 2005; revised 20 June 2005; accepted 29 June 2005

Available online 15 July 2005

Abstract— $\text{KAl}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$ was found to catalyze efficiently a one-pot three-component cyclocondensation of isatoic anhydride and primary amines or ammonia sources such as $(\text{NH}_4)_2\text{CO}_3$, NH_4OAc and NH_4Cl with aromatic aldehydes under mild conditions to afford the corresponding mono- and disubstituted 2,3-dihydroquinazolin-4(1*H*)-ones in good yields.

© 2005 Elsevier Ltd. All rights reserved.

1. Introduction

A literature survey of important and valuable physiological properties for mono- and disubstituted 2,3-dihydroquinazolin-4(1*H*)-ones includes analgesic, antitumour, anticancer, diuretic and herbicide activities.¹ In addition, these compounds can easily be oxidized to their quinazolin-4(3*H*)-one analogues,² which also include important pharmacologically active compounds.³

Several methods have been reported for the synthesis of 2,3-dihydroquinazolinones.^{3–7} However, these methods suffer from lengthy procedures and/or low yields and vigorous conditions.^{3–7}

One-pot transformations, particularly multi-component reactions (MCRs) are of current interest to organic chemists.⁸ Since the first MCR reported in 1850 by Strecker,⁹ this methodology has emerged as an especially attractive synthetic strategy for rapid and efficient library generation due to the fact that the products are formed in a single step and diversity can be achieved simply by varying the reaction components.^{8,9} MCRs leading to interesting heterocyclic scaffolds are particu-

larly useful for the creation of diverse chemical libraries of drug-like molecules for biological screening.¹⁰ Very recently, we reported the preparation of 2,3-disubstituted quinazolin-4(3*H*)-ones via multi-component reactions.¹¹ Now, we have designed a three-component one-step synthesis of 2,3-dihydroquinazolin-4(1*H*)-ones. For this, the use of $\text{KAl}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$ (alum), which is relatively non-toxic and inexpensive, was at the centre of our study. In the course of our work on applications of $\text{KAl}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$ in organic reactions, we have found that it is an effective promoter for the preparation

Table 1. Screening of Lewis acids^a

LA ^b	Time (h)	Yield ^c (%)	
		H ₂ O	EtOH
KBr	30	0	0
KCl	30	0	0
LiCl	30	0	0
LiBr	30	0	0
I ₂	30	0	0
AlCl ₃	7	25	40
$\text{NH}_4\text{Al}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$	30	21	35
$\text{KAl}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$	4	79	88


^a Yields of **4a** using different LAs in the reaction of isatoic anhydride, ethylamine and benzaldehyde.

^b For all reactions 0.5 mmol Lewis acid was used.

^c Isolated yields based on isatoic anhydride.

Keywords: $\text{KAl}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$; Multi-component reaction; Cyclocondensation; 2,3-Dihydroquinazolin-4(1*H*)-ones; Reusable catalyst.

* Corresponding author. Tel./fax: +98 21 2401765; e-mail: m-dabiri@cc.sbu.ac.ir



Scheme 1.


of mono- and disubstituted 2,3-dihydroquinazolin-4(1*H*)-ones.

When a mixture of isatoic anhydride **1**, ethylamine **2** and benzaldehyde **3** in H₂O or EtOH was stirred under reflux in the presence of a catalytic amount of alum, the reaction was completed within 1 h and 4 h, respectively. Work-up gave **4a** in 79% and 88% yields, respectively (Table 1 and Scheme 1).

After screening several Lewis acids (LAs), we found that alum was the best promoter for the reaction of isatoic anhydride **1**, ethylamine **2** and benzaldehyde **3** (Table 1).

Encouraged by this success, we examined the reaction of isatoic anhydride with a range of other aromatic aldehydes carrying either electron-releasing or electron-withdrawing substitutes, affording high yields of products. Aliphatic amines gave the products in shorter periods compared to aromatic analogues. The optimized results are summarized in Table 2.

We also checked the reusability of the catalyst by recovering the alum and using it for new runs and found that the catalyst could be reused several times without any decrease in the product yield. An example is shown for the reaction of ethylamine with isatoic anhydride and benzaldehyde (Table 2, **4a**). The catalyst can be removed from the aqueous phase by removing the water under vacuum then washing with EtOH and drying at rt.



Scheme 2.

When isatoic anhydride **1**, aromatic aldehydes **5** and ammonium salts such as ammonium carbonate, ammonium chloride and ammonium acetate were used as the source of ammonia,¹² in the presence of alum with stirring for 4–5 h in EtOH under reflux, 2-aryl substituted 2,3-dihydroquinazolin-4(1*H*)-ones **6a–g** were prepared in good yields (Scheme 2). The optimized results are summarized in Table 3.

Presumably, the reaction proceeds through condensation of isatoic anhydride **1** with primary amine **2** followed by decarboxylation to yield the corresponding 2-aminobenzamide **7**.¹³ Condensation of the aromatic aldehyde with the amino group of **7** then gives imine **8** which undergoes cyclization to afford the dihydroquinazoline product **4** (Scheme 3). Support for this mechanism was obtained when *N*-methyl isatoic anhydride **9** was reacted with ethylamine and benzaldehyde under the same conditions; only 2-*N*-methylamino ethylbenzamide¹⁵ (**7a**) was obtained (Scheme 4).

Table 2. Alum-catalyzed synthesis of 2,3-disubstituted 2,3-dihydroquinazolin-4(1*H*)-ones by the reaction of isatoic anhydride with primary amines and aromatic aldehydes



4	R ¹	R ²	Time (h)		Yield ^a (%)		Mp (°C)
			H ₂ O	EtOH	H ₂ O	EtOH	
a	Et	Ph	1	4	79, 75, 76 ^b	88, 85, 87 ^b	134–137 ^{2a}
b	Et	<i>p</i> -ClC ₆ H ₄	1	4	81	87	132–135 ^{2a}
c	Et	<i>p</i> -O ₂ NC ₆ H ₄	1	3	79	91	160–161 ^{2a}
d	Et	<i>m</i> -O ₂ NC ₆ H ₄	1	4	80	92	176–178 ^{2a}
e	Et	<i>p</i> -CH ₃ OC ₆ H ₄	1	5	70	80	124–126 ^{2a}
f	Ph	Ph	1	4	65	78	205–206 ^{7b}
g	Ph	<i>m</i> -O ₂ NC ₆ H ₄	1	5	79	85	186–188 ^{7b}
h	Ph	<i>p</i> -O ₂ NC ₆ H ₄	1	4.5	67	76	195–197 ^{7b}
i	Ph	<i>p</i> -ClC ₆ H ₄	1	5	73	81	214–217 ^{7b}
j	Me	Ph	1	4	69	78	164–165 ^{2a}
k	Me	<i>p</i> -CH ₃ OC ₆ H ₄	1	4.5	64	76	145–146 ^{2a}
l	Me	<i>p</i> -ClC ₆ H ₄	1	5	65	78	188–190 ^{2a}
m	<i>p</i> -ClC ₆ H ₄	Ph	1	4	73	80	214–216 ^{7b}
n	<i>n</i> -Pr	<i>p</i> -O ₂ NC ₆ H ₄	1	4	65	76	120–121 ¹⁵
o	Et	<i>p</i> -HOC ₆ H ₄	1	4	70	83	180–182 ¹⁵

^a Isolated yield based on isatoic anhydride.

^b The catalyst was reused for three runs.

Table 3. Alum-catalyzed synthesis of 2-aryl-2,3-dihydroquinazolin-4(1*H*)-ones by the reaction of isoic anhydride with ammonium salts and aromatic aldehydes in EtOH

6	R ³	X	Time (h)	Yield ^a (%)	Mp (°C)
a	Ph	CO ₃ ²⁻	4	83	218–220 ⁵
b	<i>p</i> -ClC ₆ H ₄	CO ₃ ²⁻	4	79	198–200 ⁵
c	<i>p</i> -CH ₃ OC ₆ H ₄	CO ₃ ²⁻	6	81	178–180 ⁵
d	<i>o</i> -CH ₃ OC ₆ H ₄	CO ₃ ²⁻	4	75	165–167 ^{1e}
e	<i>p</i> -CH ₃ C ₆ H ₄	CO ₃ ²⁻	4	76	233–234 ¹⁴
f	<i>m,p</i> -(CH ₃ O) ₂ C ₆ H ₃	CO ₃ ²⁻	4	72	210–213 ^{1e}
g	2-Furyl	CO ₃ ²⁻	4	78	165–167 ¹⁴
a	Ph	AcO ⁻	4	71	218–220 ⁵
b	<i>p</i> -ClC ₆ H ₄	AcO ⁻	5	80	198–200 ⁵
c	<i>p</i> -CH ₃ OC ₆ H ₄	AcO ⁻	6	71	178–180 ⁵
d	<i>o</i> -CH ₃ OC ₆ H ₄	AcO ⁻	4	72	165–167 ^{1e}
e	<i>p</i> -CH ₃ C ₆ H ₄	AcO ⁻	5	69	233–234 ¹⁴
f	<i>m,p</i> -(CH ₃ O) ₂ C ₆ H ₃	AcO ⁻	5	72	210–213 ^{1e}
g	2-Furyl	AcO ⁻	4	75	165–167 ¹⁴
a	Ph	Cl ⁻	4	70	218–220 ⁵
b	<i>p</i> -ClC ₆ H ₄	Cl ⁻	5	77	198–200 ⁵
c	<i>p</i> -CH ₃ OC ₆ H ₄	Cl ⁻	6	71	178–180 ⁵
d	<i>o</i> -CH ₃ OC ₆ H ₄	Cl ⁻	4	70	165–167 ^{1e}
e	<i>p</i> -CH ₃ C ₆ H ₄	Cl ⁻	5	72	233–234 ¹⁴
f	<i>m,p</i> -(CH ₃ O) ₂ C ₆ H ₃	Cl ⁻	5	74	210–213 ^{1e}
g	2-Furyl	Cl ⁻	4	73	165–167 ¹⁴

^a Isolated yield based on isoic anhydride.**Scheme 3.****Scheme 4.**

In conclusion, we have described a successful strategy for the efficient and convenient synthesis of mono- and disubstituted 2,3-dihydroquinazolinones in a one-pot, three-component cyclocondensation reaction of isoic anhydride, aromatic aldehydes and primary amines or ammonium salts using the inexpensive, non-toxic and easily available $\text{KAl}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$ as catalyst in H_2O or EtOH. The method offers several advantages including high yields of products, a recyclable catalyst and an easy experimental work-up procedure.

2. General procedure

Preparation of mono- and disubstituted 2,3-dihydroquinazolin-4(1*H*)-ones in EtOH. To a solution of isoic anhydride (1 mmol), primary amine (1.1 mmol) or an ammonium salt (ammonium carbonate 0.6 mmol, ammonium acetate 1.2 mmol or ammonium chloride 1.2 mmol) and aldehyde (1 mmol) in ethanol (5 mL) was added alum (0.15 g, 0.4 mmol). The mixture was heated at reflux for the specified period of time (see

Tables 2 and 3). After completion of the reaction as indicated by TLC (eluent: 1/3 ethyl acetate–*n*-hexane), the solid catalyst was separated by filtration. Water (10 mL) was added and the precipitated product was filtered and recrystallized from EtOH.¹⁵

Preparation of 2,3-disubstituted 2,3-dihydroquinazoline-4(1*H*)-ones in H₂O. Alum (0.2 g) was added to a mixture of isatoic anhydride (1 mmol), primary amine (1.1 mmol) and aldehyde (1 mmol) in water. The mixture was heated at reflux for 1 h (see Table 2). After completion of the reaction, the solid residue was separated, washed with water (10 mL) and recrystallized from ethanol.

Acknowledgement

Financial support from the Research Council of Shahid Beheshti University is gratefully acknowledged.

References and notes

- (a) Hour, M.; Huang, L.; Kuo, S.; Xia, Y.; Bastow, K.; Nakanishi, Y.; Hamel, E.; Lee, K. *J. Med. Chem.* **2000**, *43*, 4479–4487; (b) Misra, V. S.; Saxena, V. K.; Srivastava, R. *Indian J. Pharm. Sci.* **1983**, *45*, 207–211; (c) Kacker, I. K.; Zaheer, S. H. *J. Indian Chem. Soc.* **1951**, *28*, 344–348; (d) Gupta, R. C.; Nath, R.; Shanker, K.; Bhargava, K. P.; Kishore, K. *J. Indian Chem. Soc.* **1979**, *56*, 219–220; (e) Parmar, S. S.; Kumar, R.; Arora, R. C. *Indian J. Med. Res.* **1969**, *57*, 245–248.
- (a) Abdel-Jalil, R. J.; Volter, W.; Saeed, M. *Tetrahedron Lett.* **2004**, *45*, 3475–3476; (b) Lopez, S. E.; Rosales, M. E.; Urdaneta, N.; Godoy, M. V.; Charris, J. E. *J. Chem. Res. (S)* **2000**, 258–259; (c) Rao, V. B.; Hanumanthu, P.; Rantnam, C. V. *Indian J. Chem.* **1979**, *18B*, 493–496.
- (a) John, S. *Pharmazie* **1981**, *36*, 583–596; (b) Mannschreck, A.; Koller, H.; Stuhler, G.; Davies, M. A.; Traber, J. E. *J. Med. Chem.* **1994**, *19*, 381–383; (c) Sharma, S. D.; Kaur, V. *Synthesis* **1989**, 677–680; (d) Cizmarik, J.; Trupe, J. *Pharmazie* **1987**, *42*, 139–140; (e) Kung, P. P.; Casper, M. D.; Cook, K. L.; Willson-Lin-gardo, L. *J. Med. Chem.* **1999**, *42*, 4705–4713; (f) Corbett, J. W.; Ko, S. S.; Rodgers, J. D.; Gearhart, L. A.; Magnus, N. A.; Bachheler, L. T.; Diamond, S.; Jeffey, S.; Trainor, G. L.; Anderson, P. S.; Erickson-Vitanen, K. *J. Med. Chem.* **2000**, *43*, 2019–2030; (g) Liu, J. F.; Lee, J.; Dalton, A. M.; Bi, G.; Yu, L.; Baldino, C. M.; McElory, E.; Brown, M. *Tetrahedron Lett.* **2005**, *46*, 1241–1244.
- Moore, J. A.; Sutherland, G. J.; Sowerby, R.; Kelly, E. G.; Palermo, S.; Webster, W. *J. Org. Chem.* **1969**, 887–892.
- Su, W.; Yang, B. *Aust. J. Chem.* **2002**, *55*, 695–697.
- Shi, D.; Rong, L.; Wang, J.; Zhuang, Q.; Wang, X.; Hu, H. *Tetrahedron Lett.* **2003**, *44*, 3199–3201.
- (a) Sadanandam, Y. S.; Reddy, K. R. M.; Rao, A. B. *Eur. J. Org. Chem.* **1987**, *22*, 169–173; (b) Reo, V. B.; Ratnam, C. V. *Indian J. Chem.* **1979**, *18B*, 409–412.
- For reviews, see: (a) Pandey, G.; Singh, R. P.; Gary, A.; Singh, V. K. *Tetrahedron Lett.* **2005**, *46*, 2137–2140; (b) Werner, B.; Domling, A. *Molecules* **2003**, *8*, 53–66; (c) Domling, A.; Ugi, I. *Angew. Chem., Int. Ed.* **2000**, *39*, 3169–3210; (d) Kappe, C. O. *Acc. Chem. Res.* **2000**, *33*, 879–888; (e) Terret, N. K.; Gardner, M.; Gordon, D. W.; Kobylecki, R. J.; Steele, J. *Tetrahedron* **1995**, *51*, 8135–8173.
- Strecker, A. *Liebigs Ann. Chem.* **1850**, *75*, 27–45.
- (a) Domling, A. *Curr. Opin. Chem. Biol.* **2002**, *6*, 306–313; (b) Weber, L. *Drug Discovery Today* **2002**, *7*, 143–147.
- Dabiri, M.; Salehi, P.; Mohammadi, Ali A.; Baghbanzadeh, M. *Synth. Commun.* **2005**, *35*, 287–295.
- (a) Tewari, N.; Dwivedi, N.; Tripathi, R. P. *Tetrahedron Lett.* **2004**, *45*, 9011–9014; (b) Zolfigol, M. A.; Safaiee, M. *Synlett* **2004**, 827–828.
- Dabiri, M.; Salehi, P.; Mohammadi, Ali A.; Baghbanzadeh, M.; Khozehgiry, Gh. *J. Chem. Res. (S)* **2004**, 570–572.
- Yale, L. H.; Kalkstein, M. *J. Med. Chem.* **1967**, *10*, 334–336.
- C₁₇H₁₇N₃O₃ **4n**: IR (KBr) ($\nu_{\max}$, cm⁻¹): 3420, 1680 (C=O); ¹H NMR (CDCl₃, 500 MHz) δ_{H} : 0.94 (3H, t, *J* = 7.3 Hz), 1.64 (2H, m), 2.77 (1H, ddd, *J* = 14.1, 8.59, 5.8 Hz), 4.05 (1H, ddd, *J* = 13.9, 8.7, 6.6 Hz), 5.82 (1H, s, CH), 6.5–8.2 (8H, m, arom); ¹³C NMR (CDCl₃) δ_{C} : 12.5, 22.3, 48.1, 71.9, 116.0, 117.4, 120.9, 125.3 (2C), 128.3 (2C), 129.5, 134.9, 145.4, 148.3, 149.2, 164.1 (C=O); MS (*m/z*, %): 311 (M⁺, 64), 174 (47.6), 119 (45.2), 105 (44.3), 77 (51.6). C₁₆H₁₆O₂N₂ **4o**: IR (KBr) ($\nu_{\max}$, cm⁻¹): 3440, 1680 (C=O); ¹H NMR (DMSO-*d*₆, 500 MHz) δ_{H} : 1.0 (3H, t, CH₃, *J* = 7.08 Hz), 2.83 (1H, dq, *J* = 13.6, 7.02 Hz), 3.71 (dq, 1H, *J* = 13.6, 7.16 Hz), 5.73 (1H, d, *J* = 1.9 Hz), 6.6–6.7 (4H, m), 7.11–7.18 (3H, m), 7.20 (1H, d, *J* = 1.9, NH), 7.62 (1H, dd, *J* = 7.6, 1.4 Hz), 9.48 (1H, s, OH); ¹³C NMR (DMSO-*d*₆) δ_{C} : 14.6, 71.6, 115.6, 116.3, 116.7 (2C), 118.5, 128.9, 129.3 (2C), 133.0, 134.4, 148.1, 159.2, 163.3 (C=O); MS (*m/z*, %): 268 (M⁺, 60), 174 (67.1), 105 (53.5), 77 (40.5). C₁₀H₁₄N₂O **7a**: mp 88–90 °C; IR (KBr) ($\nu_{\max}$, cm⁻¹): 3440, 3290, 1620 (C=O); ¹H NMR (CDCl₃, 500 MHz) δ_{H} : 1.24 (3H, t, *J* = 1.25 Hz), 2.98 (3H, s), 3.45 (2H, q, *J* = 7.25 Hz), 6.03 (1H, br d, NH), 6.5–7.3 (4H, m), 7.49 (1H, br d, NH); ¹³C NMR (CDCl₃) δ_{C} : 14.9, 29.7, 34.5, 111.1, 114.5, 115.4, 127.0, 132.6, 150.3, 169.8; MS (*m/z*, %): 178 (M⁺, 70), 119 (60.4), 104 (69.5), 77 (52.2).